

## **Centers for Medicare and Medicaid Services Average Sales Price Survey**

**PURPOSE:** The results of this survey will be used in part to evaluate the average acquisition costs for specified covered outpatient drugs (SCODs) purchased by hospitals under the 340B Program.

**AUTHORITY:** Section 1833(t)(14)(D)(ii) of the Social Security Act.

**Survey Response Period:** March 23, 2020 through April 10, 2020.

### **WHO SHOULD FILL OUT THIS FORM?**

Hospitals that purchase drugs through the 340B Program, a federal government program that requires certain drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices, may also receive payment for items and services furnished to Medicare beneficiaries, including 340B-acquired drugs. Any hospital that was enrolled in the 340B program as a covered entity in the last quarter of 2018 and/or the first quarter of 2019 is required to complete the survey.

Please note that we are only requesting acquisition cost data for drugs acquired through the 340B Drug Pricing program and not any other program. We understand that as a requirement of participating in the 340B Drug Pricing Program, covered entities are required to maintain accurate records documenting compliance with all 340B Program requirements including only providing 340B Drugs to patients of the eligible entity. Accordingly, each hospital should have readily available access to the data that is being requested via this survey.

### **WHAT INFORMATION IS REQUIRED?**

For each applicable hospital, the survey shall reflect the net acquisition cost for **each** SCOD acquired under the 340B program, (that is, the sub-ceiling price after all applicable discounts/rebates). The acquisition cost should be reported regardless of whether or not the drug was dispensed at all or whether the drug was dispensed in multiple settings and regardless of how it was purchased (such as in a replenishment model under the 340B program). We are only requesting the acquisition cost of the drugs acquired under the 340B program during the specified timeframe listed below. Drugs acquired outside of the 340B program should not be included on the survey.

### **CONFIDENTIALITY**

CMS pledges to maintain confidentiality of individual responses that include acquisition prices for each SCOD to the extent provided by law. However, CMS may make public average acquisition prices reported for each SCOD. To the extent that acquisition prices for certain SCODs are deemed sensitive and/or confidential, we do not intend to make such prices available in an individually identifiable manner.

The survey is an Excel spreadsheet that will be available for download from each Medicare Administrative Contractor (MAC) website(s) that is listed at the end of the Instruction Sheet.

In the spreadsheet tab "Hospital Information," please provide the following information:

**Hospital Name:**

**CCN (Medicare Provider Number):**

**Contact Name:**

**Contact Title:**

**Hospital Address:**

**Email:**

**Phone Number:**

### **INSTRUCTIONS FOR FILLING OUT SURVEY**

Please complete the Excel spreadsheet. In the spreadsheet tab entitled "Survey", please provide the following information:

**1. Provider CCN Number:**

- a. Enter the hospital's Medicare CMS Certification Number (CCN)

**2. HCPCS code for each Drug**

- a. For each SCOD HCPCS code assigned to status indicator "K" or "G" on the files listed below, list the healthcare common procedure coding system code (HCPCS).
    - Examples:
      - HCPCS code "J0885" represents epoetin alfa.
      - HCPCS code "J0878" represents daptomycin.
  - b. Exclusions: Please exclude vaccines from the survey responses.
  - c. For 2018, the applicable HCPCS codes for each SCOD may be found on the October 2018 Addendum B found on the CMS website:  
<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html>
  - d. For 2019, the applicable HCPCS codes for each SCOD may be found on the January 2019 Addendum B found on the CMS website:  
<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html>
- Tip: To narrow the selection, filter Addendum B, column C "SI", for "K" and "G" only. This will help narrow the search.

**3. Drug Name/ Short Descriptor**

Enter the Short Descriptor of the drug that corresponds to the HCPCS number identified  
Form CMS-10709 (Exp. TBD)  
OMB control number: 0938-New

in the previous field. The short descriptor for each SCOD is located in the column entitled “Short Descriptor” in Addendum B.

Tip: Copy the short descriptor in Column B of Addendum B and paste into column C of the drug survey.

**4. Dose (as reflected in HCPCS dose descriptor)**

- a. This is the amount of drug to which the acquisition cost corresponds. List the HCPCS dosage for each drug as reflected in the HCPCS long descriptor or the “HCPCS Dosage” identified in the crosswalk files discussed below. For example, the amount of drug used for reporting J0885, epoetin alfa, is 1,000 units.

**5. NDC (National Drug Code)—Optional.**

- a. You may choose to include the National Drug Code (NDC), but doing so is optional. Your organization may have multiple NDCs for each HCPCS code depending on your acquisition. Please note that CMS publishes quarterly NDC-HCPCS Crosswalk files that are available on the CMS website. Due to an operational lag time that exists between the manufacturers' reporting of the NDCs/ASPs and their CMS publication, the October 2018 HCPCS codes do not correspond to the October 2018 ASP NDC-HCPCS Crosswalk.
  - For HCPCS codes listed in the October 2018 Addendum B, corresponding NDC crosswalk files appear under the [April 2019 ASP NDC-HCPCS Crosswalk](#).
  - For HCPCS codes listed in the January 2019 Addendum B, corresponding NDC crosswalk files appear under the [July 2019 ASP NDC-HCPCS Crosswalk](#).
  - The April 2019 and July 2019 Crosswalks appear in the Related links section for the following CMS webpage:  
<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2019ASPFiles>
- b. The April 2019 and July 2019 crosswalk files each contain 10 files. Combining the following three files from each quarter will create a list of NDCs associated with the majority of HCPCS codes that are billed under OPPS:
  - AWP NDC-HCPCS Crosswalk
  - ASP NDC-HCPCS Crosswalk
  - OPPS NDC-HCPCS Crosswalk

Please note that although the NDC-HCPCS crosswalk files provide examples of commonly associated NDCs for the majority of the HCPCS codes, these files do not provide a complete and comprehensive list of all available NDCs for each HCPCS code. Thus, respondents may include acquisition costs for additional NDCs associated to a given HCPCS code.

- c. Please be sure to utilize the most recent versions of the crosswalk files in the hyperlinks above. Some of the crosswalk files have been updated very recently.

**6. Q4 2018 Payment Rate**

- a. The payment rate may be obtained from the OPPS Addendum B for Q4 2018

**7. Q1 2019 Payment Rate**

Form CMS-10709 (Exp. TBD)

OMB control number: 0938-New

- a. The payment rate may be obtained from the OPPS Addendum B for Q1 2019

**8. Average 340B Price of Drug for Q4 of CY 2018 (October 1, 2018-December 31, 2018)**

- a. For each SCOD purchased under the 340B Program at any time during the 4th quarter of 2018 (October 1, 2018- December 31, 2018), enter the average acquisition cost for that SCOD as identified by the SCOD's Healthcare Common Procedure Coding System (HCPCS) code for the amount corresponding to a single billing unit of the corresponding HCPCS billing code.
  - The amount of drug represented by a single billing unit of a HCPCS code, also referred to as the HCPCS code dosage, can be found in the "HCPCS Dosage" column of the NDC-HCPCS Crosswalk files mentioned above.
- b. If the acquisition cost for the SCOD is unknown, you may leave this field blank and CMS will use the 340B ceiling price as a proxy for the acquisition cost for that drug.

**9. Average 340B Price of Drug for Q1 of CY 2019 (January 1, 2019- March 31, 2019)**

- a. For each SCOD purchased under the 340B Program at any time during the first quarter of 2019 (January 1, 2019- March 30, 2019), enter the average acquisition cost for that SCOD as identified by the SCOD's Healthcare Common Procedure Coding System (HCPCS) code for the amount corresponding to a single billing unit of the corresponding HCPCS billing code.
  - The amount of drug represented by a single billing unit of a HCPCS code, also referred to as the HCPCS code dosage, can be found in the "HCPCS Dosage" column of the NDC-HCPCS Crosswalk files mentioned above.
- b. If the acquisition cost for the SCOD is unknown, you may leave this field blank and CMS will use the 340B ceiling price as a proxy for the acquisition cost for that drug.

**Completed surveys should be submitted to your MAC no later than Monday, April 10, 2020.**

## Calculation Examples

1. HCPCS code J0885 (Injection, epoetin alfa, (for non-esrd use), 1000 units) include products sold under the brand names Epogen and Procrit. The drug products are sold in a variety of amounts, including vials and syringes that contain between 2000 units and 40,000 units of epoetin packaged in amounts that vary from 4 to 25 vials. On the CMS NDC-HCPCS Crosswalk files, the "HCPCS Dosage" column indicates that CMS payment of J0885 to outpatient hospitals (and other providers billing Part B by HCPCS codes) is based on 1,000 units of epoetin. For the survey, CMS is seeking the 340B average acquisition cost of J0885 per 1,000 units. Therefore, if the acquisition cost of a package of ten 20,000 unit epoetin vials is \$1800, the acquisition cost of each 20,000 unit epoetin vial in the 10 vial package is \$180. For reporting, the acquisition cost per 1,000 units of epoetin (corresponding to the amount in the HCPCS dosage as well as the HCPCS code dose descriptor) would be \$180 divided by 20, or \$9.00.
2. HCPCS code J0878 (Injection, daptomycin, 1mg). Daptomycin is commonly sold in 350 mg or 500 mg vials packed in quantities ranging from 1 to 10 vials. The survey is seeking the acquisition cost of daptomycin based on 1 mg of the drug. If a package of ten 350 mg vial is acquired for \$1400, then the acquisition cost a single 350 mg vial from the package is \$140. The acquisition cost per 1 mg of daptomycin in the HCPCS dosage or dose descriptor, 1 mg, is \$0.40.

## Medicare Administrative Contractor (MAC) websites

### A/B MAC Jurisdiction Website:

1. Jurisdiction 5  
Wisconsin Physicians Service Government Health Administrators  
<https://www.wpsgha.com/wps/portal/mac/site/home/>
2. Jurisdiction 6  
National Government Services, Inc.  
<https://www.ngsmedicare.com/ngs/portal/ngsmedicare/newngs/entry/>
3. Jurisdiction 8  
Wisconsin Physicians Service Government Health Administrators  
<https://www.wpsgha.com/wps/portal/mac/site/home/>
4. Jurisdiction 15  
CGS Administrators, LLC  
<https://cgsmedicare.com/>
5. Jurisdiction E  
Noridian Healthcare Solutions, LLC,  
<https://med.noridianmedicare.com/>
6. Jurisdiction F  
Noridian Healthcare Solutions, LLC  
<https://med.noridianmedicare.com/>
7. Jurisdiction H  
Novitas Solutions, Inc.  
[https://www.novitas-solutions.com/webcenter/portal/NovitasSolutions?\\_adf.ctrl-state=8qipjgz81\\_54](https://www.novitas-solutions.com/webcenter/portal/NovitasSolutions?_adf.ctrl-state=8qipjgz81_54)
8. Jurisdiction J  
Palmetto GBA, LLC  
<https://palmettogba.com/>
9. Jurisdiction K  
(National Government Services, Inc.)  
<https://www.ngsmedicare.com/ngs/portal/ngsmedicare/newngs/entry/>
10. Jurisdiction L  
Novitas Solutions, Inc.  
[https://www.novitas-solutions.com/webcenter/portal/NovitasSolutions?\\_adf.ctrl-state=8qipjgz81\\_4](https://www.novitas-solutions.com/webcenter/portal/NovitasSolutions?_adf.ctrl-state=8qipjgz81_4)

11. Jurisdiction M

Palmetto GBA, LLC

<https://palmettogba.com/>

12. Jurisdiction N

First Coast Service Options, Inc.

<https://www.fcso.com/>

**If you have any questions regarding the survey, please contact your local Medicare  
Administrative Contractor**

**PRA Disclosure Statement**

According to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. The valid OMB control number for this information collection is **0938-XXXX (Expires XX/XX/XXXX)**. The time required to complete this information collection is estimated to average **[Insert Time (hours or minutes)]** per response, including the time to review instructions, search existing data resources, gather the data needed, and complete and review the information collection. If you have comments concerning the accuracy of the time estimate(s) or suggestions for improving this form, please write to: CMS, 7500 Security Boulevard, Attn: PRA Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850. **\*\*\*\*CMS Disclosure\*\*\*\* Please do not send applications, claims, payments, medical records or any documents containing sensitive information to the PRA Reports Clearance Office. Please note that any correspondence not pertaining to the information collection burden approved under the associated OMB control number listed on this form will not be reviewed, forwarded, or retained. If you have questions or concerns regarding where to submit your documents, please contact your local Medicare Administrative Contractor.**